Angevin E, et al. – The maximum tolerated dose (MTD), dose–limiting toxicities (DLTs), safety, pharmacokinetics (PK) and antitumour activity of LY2780301 plus gemcitabine were examined in patients with advanced/metastatic solid tumours. The combination of LY2780301 and gemcitabine had manageable toxicity and encouraging antitumour activity in patients with molecular alterations of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway.